nodes	percent_of_prediction	percent_of_DWPC	metapath
Bezafibrate—Balsalazide—Sulfasalazine—ankylosing spondylitis	0.556	1	CrCrCtD
Bezafibrate—PPARG—Sulfasalazine—ankylosing spondylitis	0.218	0.502	CbGbCtD
Bezafibrate—SLCO1B1—Sulfasalazine—ankylosing spondylitis	0.0748	0.172	CbGbCtD
Bezafibrate—SLCO1B1—Methotrexate—ankylosing spondylitis	0.03	0.0691	CbGbCtD
Bezafibrate—CYP1A1—Dexamethasone—ankylosing spondylitis	0.0274	0.0631	CbGbCtD
Bezafibrate—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0169	0.039	CbGbCtD
Bezafibrate—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0158	0.0364	CbGbCtD
Bezafibrate—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0128	0.0296	CbGbCtD
Bezafibrate—CYP3A4—Betamethasone—ankylosing spondylitis	0.011	0.0254	CbGbCtD
Bezafibrate—CYP3A4—Prednisolone—ankylosing spondylitis	0.0109	0.025	CbGbCtD
Bezafibrate—CYP3A4—Prednisone—ankylosing spondylitis	0.0103	0.0236	CbGbCtD
Bezafibrate—CYP3A4—Dexamethasone—ankylosing spondylitis	0.00641	0.0148	CbGbCtD
Bezafibrate—Blood alkaline phosphatase increased—Methylprednisolone—ankylosing spondylitis	0.000147	0.0153	CcSEcCtD
Bezafibrate—Vascular purpura—Triamcinolone—ankylosing spondylitis	0.000143	0.0149	CcSEcCtD
Bezafibrate—Purpura—Triamcinolone—ankylosing spondylitis	0.000133	0.0138	CcSEcCtD
Bezafibrate—Muscular weakness—Prednisolone—ankylosing spondylitis	0.000123	0.0128	CcSEcCtD
Bezafibrate—Migraine—Dexamethasone—ankylosing spondylitis	0.000114	0.0119	CcSEcCtD
Bezafibrate—Migraine—Betamethasone—ankylosing spondylitis	0.000114	0.0119	CcSEcCtD
Bezafibrate—Vascular purpura—Prednisone—ankylosing spondylitis	0.000113	0.0118	CcSEcCtD
Bezafibrate—Muscular weakness—Triamcinolone—ankylosing spondylitis	0.000113	0.0118	CcSEcCtD
Bezafibrate—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.000112	0.0117	CcSEcCtD
Bezafibrate—Muscular weakness—Methylprednisolone—ankylosing spondylitis	0.000112	0.0117	CcSEcCtD
Bezafibrate—Influenza—Triamcinolone—ankylosing spondylitis	0.00011	0.0115	CcSEcCtD
Bezafibrate—Bronchitis—Triamcinolone—ankylosing spondylitis	0.000106	0.0111	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Prednisolone—ankylosing spondylitis	0.000106	0.011	CcSEcCtD
Bezafibrate—Myocardial infarction—Prednisolone—ankylosing spondylitis	0.000105	0.011	CcSEcCtD
Bezafibrate—Purpura—Prednisone—ankylosing spondylitis	0.000105	0.0109	CcSEcCtD
Bezafibrate—Muscular weakness—Betamethasone—ankylosing spondylitis	0.000102	0.0107	CcSEcCtD
Bezafibrate—Muscular weakness—Dexamethasone—ankylosing spondylitis	0.000102	0.0107	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Triamcinolone—ankylosing spondylitis	9.71e-05	0.0101	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Methylprednisolone—ankylosing spondylitis	9.68e-05	0.0101	CcSEcCtD
Bezafibrate—Myocardial infarction—Triamcinolone—ankylosing spondylitis	9.65e-05	0.0101	CcSEcCtD
Bezafibrate—Myocardial infarction—Methylprednisolone—ankylosing spondylitis	9.63e-05	0.0101	CcSEcCtD
Bezafibrate—Photosensitivity—Methotrexate—ankylosing spondylitis	9.61e-05	0.01	CcSEcCtD
Bezafibrate—Renal failure acute—Methotrexate—ankylosing spondylitis	9.14e-05	0.00955	CcSEcCtD
Bezafibrate—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	8.9e-05	0.0093	CcSEcCtD
Bezafibrate—Muscular weakness—Prednisone—ankylosing spondylitis	8.9e-05	0.0093	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Dexamethasone—ankylosing spondylitis	8.81e-05	0.0092	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Betamethasone—ankylosing spondylitis	8.81e-05	0.0092	CcSEcCtD
Bezafibrate—Pharyngitis—Triamcinolone—ankylosing spondylitis	8.77e-05	0.00916	CcSEcCtD
Bezafibrate—Myocardial infarction—Dexamethasone—ankylosing spondylitis	8.76e-05	0.00915	CcSEcCtD
Bezafibrate—Myocardial infarction—Betamethasone—ankylosing spondylitis	8.76e-05	0.00915	CcSEcCtD
Bezafibrate—Erythema—Prednisolone—ankylosing spondylitis	8.37e-05	0.00874	CcSEcCtD
Bezafibrate—Erectile dysfunction—Prednisone—ankylosing spondylitis	8.04e-05	0.00839	CcSEcCtD
Bezafibrate—Liver function test abnormal—Methotrexate—ankylosing spondylitis	7.79e-05	0.00814	CcSEcCtD
Bezafibrate—Erythema—Triamcinolone—ankylosing spondylitis	7.69e-05	0.00804	CcSEcCtD
Bezafibrate—Erythema—Methylprednisolone—ankylosing spondylitis	7.68e-05	0.00802	CcSEcCtD
Bezafibrate—Acute coronary syndrome—Prednisone—ankylosing spondylitis	7.67e-05	0.00801	CcSEcCtD
Bezafibrate—Myocardial infarction—Prednisone—ankylosing spondylitis	7.63e-05	0.00797	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Methotrexate—ankylosing spondylitis	7.6e-05	0.00794	CcSEcCtD
Bezafibrate—Alopecia—Dexamethasone—ankylosing spondylitis	7.09e-05	0.0074	CcSEcCtD
Bezafibrate—Alopecia—Betamethasone—ankylosing spondylitis	7.09e-05	0.0074	CcSEcCtD
Bezafibrate—Erythema—Dexamethasone—ankylosing spondylitis	6.98e-05	0.00729	CcSEcCtD
Bezafibrate—Erythema—Betamethasone—ankylosing spondylitis	6.98e-05	0.00729	CcSEcCtD
Bezafibrate—Pancytopenia—Methotrexate—ankylosing spondylitis	6.93e-05	0.00723	CcSEcCtD
Bezafibrate—Erectile dysfunction—Methotrexate—ankylosing spondylitis	6.72e-05	0.00702	CcSEcCtD
Bezafibrate—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	6.66e-05	0.00695	CcSEcCtD
Bezafibrate—Myalgia—Triamcinolone—ankylosing spondylitis	6.55e-05	0.00684	CcSEcCtD
Bezafibrate—Myalgia—Methylprednisolone—ankylosing spondylitis	6.54e-05	0.00683	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	6.45e-05	0.00673	CcSEcCtD
Bezafibrate—Infection—Triamcinolone—ankylosing spondylitis	6.24e-05	0.00652	CcSEcCtD
Bezafibrate—Infection—Methylprednisolone—ankylosing spondylitis	6.22e-05	0.0065	CcSEcCtD
Bezafibrate—Insomnia—Prednisolone—ankylosing spondylitis	6.18e-05	0.00645	CcSEcCtD
Bezafibrate—Alopecia—Prednisone—ankylosing spondylitis	6.17e-05	0.00645	CcSEcCtD
Bezafibrate—Erythema—Prednisone—ankylosing spondylitis	6.08e-05	0.00635	CcSEcCtD
Bezafibrate—Myalgia—Betamethasone—ankylosing spondylitis	5.94e-05	0.00621	CcSEcCtD
Bezafibrate—Myalgia—Dexamethasone—ankylosing spondylitis	5.94e-05	0.00621	CcSEcCtD
Bezafibrate—Pain—Prednisolone—ankylosing spondylitis	5.84e-05	0.0061	CcSEcCtD
Bezafibrate—Pharyngitis—Methotrexate—ankylosing spondylitis	5.79e-05	0.00605	CcSEcCtD
Bezafibrate—Urinary tract disorder—Methotrexate—ankylosing spondylitis	5.76e-05	0.00602	CcSEcCtD
Bezafibrate—Urethral disorder—Methotrexate—ankylosing spondylitis	5.72e-05	0.00598	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	5.72e-05	0.00598	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	5.71e-05	0.00596	CcSEcCtD
Bezafibrate—Insomnia—Triamcinolone—ankylosing spondylitis	5.68e-05	0.00593	CcSEcCtD
Bezafibrate—Insomnia—Methylprednisolone—ankylosing spondylitis	5.67e-05	0.00592	CcSEcCtD
Bezafibrate—Infection—Dexamethasone—ankylosing spondylitis	5.66e-05	0.00591	CcSEcCtD
Bezafibrate—Infection—Betamethasone—ankylosing spondylitis	5.66e-05	0.00591	CcSEcCtD
Bezafibrate—Anaemia—Prednisone—ankylosing spondylitis	5.62e-05	0.00587	CcSEcCtD
Bezafibrate—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	5.58e-05	0.00583	CcSEcCtD
Bezafibrate—Thrombocytopenia—Betamethasone—ankylosing spondylitis	5.58e-05	0.00583	CcSEcCtD
Bezafibrate—Dyspepsia—Triamcinolone—ankylosing spondylitis	5.53e-05	0.00577	CcSEcCtD
Bezafibrate—Erythema multiforme—Methotrexate—ankylosing spondylitis	5.52e-05	0.00576	CcSEcCtD
Bezafibrate—Dyspepsia—Methylprednisolone—ankylosing spondylitis	5.52e-05	0.00576	CcSEcCtD
Bezafibrate—Urticaria—Prednisolone—ankylosing spondylitis	5.42e-05	0.00567	CcSEcCtD
Bezafibrate—Pain—Triamcinolone—ankylosing spondylitis	5.37e-05	0.00561	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	5.19e-05	0.00542	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	5.19e-05	0.00542	CcSEcCtD
Bezafibrate—Myalgia—Prednisone—ankylosing spondylitis	5.18e-05	0.00541	CcSEcCtD
Bezafibrate—Alopecia—Methotrexate—ankylosing spondylitis	5.16e-05	0.00539	CcSEcCtD
Bezafibrate—Insomnia—Dexamethasone—ankylosing spondylitis	5.15e-05	0.00538	CcSEcCtD
Bezafibrate—Insomnia—Betamethasone—ankylosing spondylitis	5.15e-05	0.00538	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	5.12e-05	0.00535	CcSEcCtD
Bezafibrate—Erythema—Methotrexate—ankylosing spondylitis	5.08e-05	0.00531	CcSEcCtD
Bezafibrate—Hypersensitivity—Prednisolone—ankylosing spondylitis	5.03e-05	0.00525	CcSEcCtD
Bezafibrate—Dyspepsia—Betamethasone—ankylosing spondylitis	5.02e-05	0.00524	CcSEcCtD
Bezafibrate—Dyspepsia—Dexamethasone—ankylosing spondylitis	5.02e-05	0.00524	CcSEcCtD
Bezafibrate—Urticaria—Triamcinolone—ankylosing spondylitis	4.99e-05	0.00521	CcSEcCtD
Bezafibrate—Urticaria—Methylprednisolone—ankylosing spondylitis	4.98e-05	0.0052	CcSEcCtD
Bezafibrate—Abdominal pain—Methylprednisolone—ankylosing spondylitis	4.95e-05	0.00517	CcSEcCtD
Bezafibrate—Infection—Prednisone—ankylosing spondylitis	4.93e-05	0.00515	CcSEcCtD
Bezafibrate—Pain—Dexamethasone—ankylosing spondylitis	4.87e-05	0.00509	CcSEcCtD
Bezafibrate—Pain—Betamethasone—ankylosing spondylitis	4.87e-05	0.00509	CcSEcCtD
Bezafibrate—Anaemia—Methotrexate—ankylosing spondylitis	4.7e-05	0.00491	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	4.66e-05	0.00487	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	4.66e-05	0.00487	CcSEcCtD
Bezafibrate—Hypersensitivity—Triamcinolone—ankylosing spondylitis	4.63e-05	0.00483	CcSEcCtD
Bezafibrate—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	4.62e-05	0.00482	CcSEcCtD
Bezafibrate—Urticaria—Betamethasone—ankylosing spondylitis	4.53e-05	0.00473	CcSEcCtD
Bezafibrate—Urticaria—Dexamethasone—ankylosing spondylitis	4.53e-05	0.00473	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	4.52e-05	0.00472	CcSEcCtD
Bezafibrate—Dizziness—Prednisolone—ankylosing spondylitis	4.52e-05	0.00472	CcSEcCtD
Bezafibrate—Abdominal pain—Dexamethasone—ankylosing spondylitis	4.5e-05	0.0047	CcSEcCtD
Bezafibrate—Abdominal pain—Betamethasone—ankylosing spondylitis	4.5e-05	0.0047	CcSEcCtD
Bezafibrate—Insomnia—Prednisone—ankylosing spondylitis	4.49e-05	0.00469	CcSEcCtD
Bezafibrate—Pruritus—Triamcinolone—ankylosing spondylitis	4.44e-05	0.00464	CcSEcCtD
Bezafibrate—Pruritus—Methylprednisolone—ankylosing spondylitis	4.43e-05	0.00463	CcSEcCtD
Bezafibrate—Dyspepsia—Prednisone—ankylosing spondylitis	4.37e-05	0.00456	CcSEcCtD
Bezafibrate—Myalgia—Methotrexate—ankylosing spondylitis	4.33e-05	0.00452	CcSEcCtD
Bezafibrate—Rash—Prednisolone—ankylosing spondylitis	4.31e-05	0.0045	CcSEcCtD
Bezafibrate—Dermatitis—Prednisolone—ankylosing spondylitis	4.3e-05	0.00449	CcSEcCtD
Bezafibrate—Diarrhoea—Methylprednisolone—ankylosing spondylitis	4.29e-05	0.00448	CcSEcCtD
Bezafibrate—Headache—Prednisolone—ankylosing spondylitis	4.28e-05	0.00447	CcSEcCtD
Bezafibrate—Constipation—Prednisone—ankylosing spondylitis	4.24e-05	0.00443	CcSEcCtD
Bezafibrate—Dizziness—Triamcinolone—ankylosing spondylitis	4.15e-05	0.00434	CcSEcCtD
Bezafibrate—Dizziness—Methylprednisolone—ankylosing spondylitis	4.14e-05	0.00433	CcSEcCtD
Bezafibrate—Infection—Methotrexate—ankylosing spondylitis	4.12e-05	0.0043	CcSEcCtD
Bezafibrate—Thrombocytopenia—Methotrexate—ankylosing spondylitis	4.06e-05	0.00424	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Prednisone—ankylosing spondylitis	4.06e-05	0.00424	CcSEcCtD
Bezafibrate—Nausea—Prednisolone—ankylosing spondylitis	4.06e-05	0.00424	CcSEcCtD
Bezafibrate—Pruritus—Betamethasone—ankylosing spondylitis	4.03e-05	0.00421	CcSEcCtD
Bezafibrate—Pruritus—Dexamethasone—ankylosing spondylitis	4.03e-05	0.00421	CcSEcCtD
Bezafibrate—Rash—Triamcinolone—ankylosing spondylitis	3.96e-05	0.00414	CcSEcCtD
Bezafibrate—Dermatitis—Triamcinolone—ankylosing spondylitis	3.96e-05	0.00413	CcSEcCtD
Bezafibrate—Rash—Methylprednisolone—ankylosing spondylitis	3.95e-05	0.00413	CcSEcCtD
Bezafibrate—Dermatitis—Methylprednisolone—ankylosing spondylitis	3.95e-05	0.00412	CcSEcCtD
Bezafibrate—Urticaria—Prednisone—ankylosing spondylitis	3.94e-05	0.00412	CcSEcCtD
Bezafibrate—Headache—Triamcinolone—ankylosing spondylitis	3.93e-05	0.00411	CcSEcCtD
Bezafibrate—Headache—Methylprednisolone—ankylosing spondylitis	3.93e-05	0.0041	CcSEcCtD
Bezafibrate—Abdominal pain—Prednisone—ankylosing spondylitis	3.92e-05	0.0041	CcSEcCtD
Bezafibrate—Diarrhoea—Dexamethasone—ankylosing spondylitis	3.9e-05	0.00407	CcSEcCtD
Bezafibrate—Diarrhoea—Betamethasone—ankylosing spondylitis	3.9e-05	0.00407	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	3.78e-05	0.00395	CcSEcCtD
Bezafibrate—Dizziness—Dexamethasone—ankylosing spondylitis	3.77e-05	0.00394	CcSEcCtD
Bezafibrate—Dizziness—Betamethasone—ankylosing spondylitis	3.77e-05	0.00394	CcSEcCtD
Bezafibrate—Insomnia—Methotrexate—ankylosing spondylitis	3.75e-05	0.00392	CcSEcCtD
Bezafibrate—Nausea—Triamcinolone—ankylosing spondylitis	3.73e-05	0.0039	CcSEcCtD
Bezafibrate—Nausea—Methylprednisolone—ankylosing spondylitis	3.72e-05	0.00389	CcSEcCtD
Bezafibrate—Hypersensitivity—Prednisone—ankylosing spondylitis	3.66e-05	0.00382	CcSEcCtD
Bezafibrate—Dyspepsia—Methotrexate—ankylosing spondylitis	3.65e-05	0.00381	CcSEcCtD
Bezafibrate—Rash—Dexamethasone—ankylosing spondylitis	3.59e-05	0.00375	CcSEcCtD
Bezafibrate—Rash—Betamethasone—ankylosing spondylitis	3.59e-05	0.00375	CcSEcCtD
Bezafibrate—Dermatitis—Dexamethasone—ankylosing spondylitis	3.59e-05	0.00375	CcSEcCtD
Bezafibrate—Dermatitis—Betamethasone—ankylosing spondylitis	3.59e-05	0.00375	CcSEcCtD
Bezafibrate—Headache—Betamethasone—ankylosing spondylitis	3.57e-05	0.00373	CcSEcCtD
Bezafibrate—Headache—Dexamethasone—ankylosing spondylitis	3.57e-05	0.00373	CcSEcCtD
Bezafibrate—Pain—Methotrexate—ankylosing spondylitis	3.55e-05	0.0037	CcSEcCtD
Bezafibrate—Pruritus—Prednisone—ankylosing spondylitis	3.51e-05	0.00367	CcSEcCtD
Bezafibrate—Diarrhoea—Prednisone—ankylosing spondylitis	3.4e-05	0.00355	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	3.39e-05	0.00354	CcSEcCtD
Bezafibrate—Nausea—Dexamethasone—ankylosing spondylitis	3.38e-05	0.00354	CcSEcCtD
Bezafibrate—Nausea—Betamethasone—ankylosing spondylitis	3.38e-05	0.00354	CcSEcCtD
Bezafibrate—Urticaria—Methotrexate—ankylosing spondylitis	3.29e-05	0.00344	CcSEcCtD
Bezafibrate—Dizziness—Prednisone—ankylosing spondylitis	3.28e-05	0.00343	CcSEcCtD
Bezafibrate—Abdominal pain—Methotrexate—ankylosing spondylitis	3.28e-05	0.00342	CcSEcCtD
Bezafibrate—Rash—Prednisone—ankylosing spondylitis	3.13e-05	0.00327	CcSEcCtD
Bezafibrate—Dermatitis—Prednisone—ankylosing spondylitis	3.13e-05	0.00326	CcSEcCtD
Bezafibrate—Headache—Prednisone—ankylosing spondylitis	3.11e-05	0.00325	CcSEcCtD
Bezafibrate—Hypersensitivity—Methotrexate—ankylosing spondylitis	3.06e-05	0.00319	CcSEcCtD
Bezafibrate—Nausea—Prednisone—ankylosing spondylitis	2.95e-05	0.00308	CcSEcCtD
Bezafibrate—Pruritus—Methotrexate—ankylosing spondylitis	2.93e-05	0.00306	CcSEcCtD
Bezafibrate—Diarrhoea—Methotrexate—ankylosing spondylitis	2.84e-05	0.00296	CcSEcCtD
Bezafibrate—Dizziness—Methotrexate—ankylosing spondylitis	2.74e-05	0.00286	CcSEcCtD
Bezafibrate—Rash—Methotrexate—ankylosing spondylitis	2.61e-05	0.00273	CcSEcCtD
Bezafibrate—Dermatitis—Methotrexate—ankylosing spondylitis	2.61e-05	0.00273	CcSEcCtD
Bezafibrate—Headache—Methotrexate—ankylosing spondylitis	2.6e-05	0.00271	CcSEcCtD
Bezafibrate—Nausea—Methotrexate—ankylosing spondylitis	2.46e-05	0.00257	CcSEcCtD
